University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

March 23, 2017

Thomas F. Gajewski, MD, PhD, discusses how the combination of PD-1 and IDO inhibitors could change the standard of care for patients with melanoma, and highlights other emerging targets on the horizon.

March 22, 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

March 21, 2017

Jason J. Luke, MD, discusses adjuvant therapy for patients with melanoma, as well as the future of targeted agents and immunotherapy.

March 21, 2017

Christopher R. Shea, MD, expresses the importance of expanding melanoma knowledge to more specialists as well as the advancements in pathology over the last several years.

March 20, 2017

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.

March 07, 2017

Stacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, University of Chicago Medicine, discusses the benefits of palliative care for patients with non–small cell lung cancer (NSCLC).

February 20, 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.

February 16, 2017

Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses different settings of patients with head and neck cancer.

February 11, 2017

Stacie Levine, MD, associate professor of Medicine, Director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, The University of Chicago Medicine, discusses a trial regarding simulation in the management of EGFR-mutated advanced NSCLC

January 24, 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the next steps researchers are taking to improve survival outcomes for patients with head and neck cancer.

January 19, 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses recent progress in the treatment landscape of head and neck cancer.

January 06, 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the possibility of moving immunotherapy agents into the frontline setting for patients with head and neck cancer.

December 28, 2016

Jason J. Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses ongoing studies exploring immunotherapy for the treatment of patients with melanoma.

December 28, 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.

December 23, 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago Medicine, discusses how the presence or absence of CD8 T cells can affect treatment approaches for patients with melanoma.

December 23, 2016

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.

December 20, 2016

Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.

December 20, 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses some of the challenges that oncologists may face when administering immunotherapy agents to patients with melanoma.

December 16, 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses immune checkpoint blockade therapies that are currently being used to treat patients with melanoma.

December 02, 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses curative treatment approaches for patients with head and neck cancer.